[go: up one dir, main page]

MX2019011639A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2019011639A
MX2019011639A MX2019011639A MX2019011639A MX2019011639A MX 2019011639 A MX2019011639 A MX 2019011639A MX 2019011639 A MX2019011639 A MX 2019011639A MX 2019011639 A MX2019011639 A MX 2019011639A MX 2019011639 A MX2019011639 A MX 2019011639A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
well
ylquinazolin
pyridazin
morpholin
Prior art date
Application number
MX2019011639A
Other languages
English (en)
Other versions
MX390792B (es
Inventor
Weigandt Markus
Geissler Simon
Jeschke Martina
Boniforte Patrizia
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019011639A publication Critical patent/MX2019011639A/es
Publication of MX390792B publication Critical patent/MX390792B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica de (S)-[2-cloro-4-fluoro-5-(7-morfolin-4- ilquinazolin-4-il)fenil] -(6-metoxi-piridazin-3-il)metanol o una sal farmacéuticamente aceptable del mismo, así como un método para elaborar la misma, así como usos médicos de la misma.
MX2019011639A 2017-03-30 2018-03-28 Formulación farmacéutica. MX390792B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163830 2017-03-30
PCT/EP2018/057877 WO2018178134A1 (en) 2017-03-30 2018-03-28 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
MX2019011639A true MX2019011639A (es) 2019-12-05
MX390792B MX390792B (es) 2025-03-21

Family

ID=58461174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011639A MX390792B (es) 2017-03-30 2018-03-28 Formulación farmacéutica.

Country Status (22)

Country Link
US (3) US11559490B2 (es)
EP (2) EP3601277B1 (es)
JP (1) JP7228524B2 (es)
KR (1) KR102708265B1 (es)
CN (1) CN110446707B (es)
AU (1) AU2018246258B2 (es)
CA (1) CA3058286A1 (es)
DK (1) DK3601277T3 (es)
ES (1) ES2968399T3 (es)
FI (1) FI3601277T3 (es)
HR (1) HRP20231748T1 (es)
HU (1) HUE064474T2 (es)
IL (2) IL301979B2 (es)
LT (1) LT3601277T (es)
MX (1) MX390792B (es)
PL (1) PL3601277T3 (es)
PT (1) PT3601277T (es)
RS (1) RS65052B1 (es)
SG (1) SG11201909062WA (es)
SI (1) SI3601277T1 (es)
TW (2) TWI808077B (es)
WO (1) WO2018178134A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2020259613A1 (zh) * 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为dna-pk抑制剂的喹啉和噌啉衍生物
WO2022058323A1 (en) 2020-09-18 2022-03-24 Merck Patent Gmbh Compounds for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509283A (ja) 2008-01-11 2011-03-24 シプラ・リミテッド 固体医薬剤形
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
IN2011CH01887A (es) * 2011-06-02 2012-12-14
LT2765990T (lt) * 2011-10-14 2018-01-25 Array Biopharma, Inc. Solidinė dispersija
WO2014125352A1 (en) * 2013-02-14 2014-08-21 Aurobindo Pharma Limited Pharmaceutical compositions comprising tadalafil
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法

Also Published As

Publication number Publication date
RU2019133789A3 (es) 2021-07-12
HUE064474T2 (hu) 2024-03-28
US20240408021A1 (en) 2024-12-12
IL269668A (en) 2019-11-28
SI3601277T1 (sl) 2024-02-29
PL3601277T3 (pl) 2024-07-08
IL301979A (en) 2023-06-01
NZ755950A (en) 2025-05-02
CA3058286A1 (en) 2018-10-04
EP4286007A3 (en) 2024-04-10
US20210085611A1 (en) 2021-03-25
US11559490B2 (en) 2023-01-24
EP3601277A1 (en) 2020-02-05
IL269668B2 (en) 2023-09-01
IL269668B1 (en) 2023-05-01
ES2968399T3 (es) 2024-05-09
CN110446707B (zh) 2024-03-08
WO2018178134A1 (en) 2018-10-04
IL301979B2 (en) 2024-05-01
KR102708265B1 (ko) 2024-09-20
JP7228524B2 (ja) 2023-02-24
TWI808077B (zh) 2023-07-11
IL301979B1 (en) 2024-01-01
AU2018246258B2 (en) 2021-07-29
RS65052B1 (sr) 2024-02-29
AU2018246258A1 (en) 2019-11-14
BR112019020269A2 (pt) 2020-04-22
CN110446707A (zh) 2019-11-12
FI3601277T3 (fi) 2024-01-09
EP3601277B1 (en) 2023-10-11
RU2019133789A (ru) 2021-04-30
DK3601277T3 (da) 2024-01-15
EP4286007A2 (en) 2023-12-06
HRP20231748T1 (hr) 2024-03-15
KR20190130017A (ko) 2019-11-20
TW202402297A (zh) 2024-01-16
LT3601277T (lt) 2024-01-25
US20230119567A1 (en) 2023-04-20
TWI871668B (zh) 2025-02-01
JP2020512367A (ja) 2020-04-23
MX390792B (es) 2025-03-21
TW201902485A (zh) 2019-01-16
PT3601277T (pt) 2024-01-11
SG11201909062WA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
CR20220251A (es) Nuevos derivados de metilquinazolinona
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX377845B (es) Inhibidores de calicreína plasmática humana.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201990833A1 (ru) Соединение пиридина
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MY194116A (en) Pharmaceutical compounds
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
MX376283B (es) Compuestos de imidazopiridazina.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
MX379245B (es) Compuesto de tres ciclos y aplicaciones del mismo
PH12016502293A1 (en) Naphthyridinedione derivatives
EA201692298A1 (ru) Производные карбоксамидов
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
ZA201907144B (en) Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MX2019011639A (es) Formulacion farmaceutica.
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
BR112017016393A2 (pt) composições farmacêuticas estáveis compreendendo agente antibacteriano